Skip to main content

Advertisement

SpringerLink
Log in

Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To validate the relationship between ABO blood type and risk of VTE post-RC in a large retrospective database.

Methods

Patients with urothelial bladder cancer (UBC) who underwent RC (intent-to-cure) for whom ABO blood type was available between 2003 and 2015 were identified from our IRB-approved database. VTE was defined as deep vein thrombosis (DVT) or pulmonary embolism (PE) within 90 days of surgery. VTE prophylaxis consisted of immediate postoperative Coumadin (2003–2009), unfractionated heparin (UFH) during hospitalization (2009–2015), and UFH during hospitalization plus 4 weeks of enoxaparin after discharge (2013–2015). Univariable and multivariable analyses of the association of ABO blood type with postoperative, symptomatic VTE and oncologic outcomes were performed.

Results

Of 1341 patients, 595 (44.4%) were ABO type O and 746 (55.6%) were non-O (A, B and AB). 90 patients were diagnosed with VTE within 90 days of surgery (6.7%) (43% DVT-only, 57% PE ± DVT). On multivariable analysis non-O blood type was associated with a nearly twofold increased risk of VTE (OR = 1.94, 95% CI 1.215–3.098, p = 0.004). No difference in recurrence-free survival or overall survival was seen between ABO groups.

Conclusion

Non-O blood type is an independent, non-modifiable risk factor for postoperative VTE after RC. More comprehensive counseling and thromboprophylaxis should be considered in this high-risk group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. VanDlac AA, Cowan NG, Chen Y, Anderson RE, Conlin MJ, La Rochelle JC, Amling CL, Koppie TM (2014) Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol 191(4):943–947. https://doi.org/10.1016/j.juro.2013.10.096

    Article  PubMed  Google Scholar 

  2. Alberts BD, Woldu SL, Weinberg AC, Danzig MR, Korets R, Badani KK (2014) Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology 84(4):799–806. https://doi.org/10.1016/j.urology.2014.05.055

    Article  PubMed  Google Scholar 

  3. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89–95

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA (2012) The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol 187(6):2011–2017. https://doi.org/10.1016/j.juro.2012.01.077

    Article  PubMed  Google Scholar 

  5. Culkin DJ, Exaire EJ, Green D, Soloway MS, Gross AJ, Desai MR, White JR, Lightner DJ (2014) Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 192(4):1026–1034. https://doi.org/10.1016/j.juro.2014.04.103

    Article  PubMed  Google Scholar 

  6. Sun AJ, Djaladat H, Schuckman A, Miranda G, Cai J, Daneshmand S (2015) Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events. J Urol 193(2):565–569. https://doi.org/10.1016/j.juro.2014.08.085

    Article  PubMed  Google Scholar 

  7. Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH (2016) Incidence, characteristics and implications of thromboembolic events in patients with muscle invasive urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. J Urol 196(6):1627–1633. https://doi.org/10.1016/j.juro.2016.06.017

    Article  PubMed  Google Scholar 

  8. Tollefson MK, Karnes RJ, Rangel L, Carlson R, Boorjian SA (2014) Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol 191(3):646–651. https://doi.org/10.1016/j.juro.2013.10.062

    Article  PubMed  Google Scholar 

  9. Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK, Tauscher CD, Tollefson MK (2014) Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology 83(1):140–145. https://doi.org/10.1016/j.urology.2013.08.046

    Article  PubMed  Google Scholar 

  10. Stein JP, Skinner DG (2004) Surgical atlas. Radical cystectomy. BJU Int 94(1):197–221. https://doi.org/10.1111/j.1464-410X.2004.04981.x

    Article  PubMed  Google Scholar 

  11. Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR, Bertina RM (2007) ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 97(4):534–541

    Article  CAS  PubMed  Google Scholar 

  12. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, Wakefield TW, Lämmle B, Massberg S, Wagner DD (2011) von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117(4):1400–1407. https://doi.org/10.1182/blood-2010-05-287623

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jenkins PV, O’Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46(10):1836–1844. https://doi.org/10.1111/j.1537-2995.2006.00975.x

    Article  CAS  PubMed  Google Scholar 

  14. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540–3545. https://doi.org/10.1182/blood-2007-11-122945

    Article  CAS  PubMed  Google Scholar 

  15. Nossent AY, van Marion V, van Tilburg NH, Rosendaal FR, Bertina RM, van Mourik JA, Eikenboom HC (2006) von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 4(12):2556–2562. https://doi.org/10.1111/j.1538-7836.2006.02273.x

    Article  CAS  PubMed  Google Scholar 

  16. Bowen DJ (2003) An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 1(1):33–40

    Article  CAS  PubMed  Google Scholar 

  17. Matsui T, Titani K, Mizuochi T (1992) Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 267(13):8723–8731

    CAS  PubMed  Google Scholar 

  18. Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, Crestani S, Franchini M (2012) Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 38(5):535–548. https://doi.org/10.1055/s-0032-1315758

    Article  PubMed  Google Scholar 

  19. De Martino RR, Goodney PP, Spangler EL, Wallaert JB, Corriere MA, Rzucidlo EM, Walsh DB, Stone DH (2012) Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 55(4):1035–1040.e1034. https://doi.org/10.1016/j.jvs.2011.10.129

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mehrazin R, Piotrowski Z, Egleston B, Parker D, Tomaszweski JJ, Smaldone MC, Abbosh PH, Ito T, Bloch P, Iffrig K, Bilusic M, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Kutikov A (2014) Is extended pharmacologic venous thromboembolism prophylaxis uniformly safe after radical cystectomy? Urology 84(5):1152–1156. https://doi.org/10.1016/j.urology.2014.06.058

    Article  PubMed  PubMed Central  Google Scholar 

  21. Violette PD, Cartwright R, Briel M, Tikkinen KA, Guyatt GH (2016) Guideline of guidelines: thromboprophylaxis for urological surgery. BJU Int 118(3):351–358. https://doi.org/10.1111/bju.13496

    Article  PubMed  Google Scholar 

  22. Tikkinen KA, Craigie S, Agarwal A, Violette PD, Novara G, Cartwright R, Naspro R, Siemieniuk RA, Ali B, Eryuzlu L, Geraci J, Winkup J, Yoo D, Gould MK, Sandset PM, Guyatt GH (2017) Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis. Eur Urol. https://doi.org/10.1016/j.eururo.2017.03.008

    Article  PubMed  Google Scholar 

  23. Rasmussen MS, Jørgensen LN, Wille-Jørgensen P (2009) Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 1:CD004318. https://doi.org/10.1002/14651858.cd004318.pub2

    Article  Google Scholar 

  24. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD (2012) Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 30(35):4416–4426. https://doi.org/10.1200/JCO.2012.42.4358

    Article  CAS  PubMed  Google Scholar 

  25. Gershman B, Moreira DM, Tollefson MK, Frank I, Cheville JC, Thapa P, Tarrell RF, Thompson RH, Boorjian SA (2016) The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Urol Oncol 34(1):4.e1-9. https://doi.org/10.1016/j.urolonc.2015.07.023

    Article  PubMed  Google Scholar 

  26. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Shariat SF (2014) Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol 32(5):625–630. https://doi.org/10.1016/j.urolonc.2013.11.010

    Article  PubMed  Google Scholar 

  27. Süer E, Özcan C, Gökçe I, Gülpınar Ö, Göğüş C, Türkölmez K, Baltacı S, Bedük Y (2014) Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol 46(8):1521–1526. https://doi.org/10.1007/s11255-014-0698-x

    Article  PubMed  Google Scholar 

  28. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, Investigators EI (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975–980. https://doi.org/10.1056/NEJMoa012385

    Article  CAS  Google Scholar 

  29. Pariser JJ, Pearce SM, Anderson BB, Packiam VT, Prachand VN, Smith ND, Steinberg GD (2017) Extended duration enoxaparin decreases the rate of venous thromboembolic events after radical cystectomy compared to inpatient only subcutaneous heparin. J Urol 197(2):302–307. https://doi.org/10.1016/j.juro.2016.08.090

    Article  CAS  PubMed  Google Scholar 

  30. Clément C, Rossi P, Aissi K, Barthelemy P, Guibert N, Auquier P, Ragni E, Rossi D, Frances Y, Bastide C (2011) Incidence, risk profile and morphological pattern of lower extremity venous thromboembolism after urological cancer surgery. J Urol 186(6):2293–2297. https://doi.org/10.1016/j.juro.2011.07.074

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA

    Sumeet Bhanvadia, Soroush T. Bazargani, Gus Miranda, Jie Cai, Siamak Daneshmand & Hooman Djaladat

  2. USC School of Medicine, Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA

    Kayvan Kazerouni

  3. University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA

    Hooman Djaladat

Authors
  1. Sumeet Bhanvadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayvan Kazerouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soroush T. Bazargani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gus Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jie Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Siamak Daneshmand
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hooman Djaladat
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SB: data management; data analysis; manuscript editing; other (critical review). KK: data collection or management; data analysis; manuscript writing/editing, STB: data collection or management; data analysis; manuscript writing/editing. GM: data collection or management; data analysis. JC: data collection or management; Data analysis. SD: protocol/project development; manuscript editing; other (critical review). HD: Protocol/project development; data management; data analysis; manuscript editing; other (critical review).

Corresponding author

Correspondence to Hooman Djaladat.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhanvadia, S., Kazerouni, K., Bazargani, S.T. et al. Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy. World J Urol 37, 173–179 (2019). https://doi.org/10.1007/s00345-018-2351-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-018-2351-2

Keywords

Search

Navigation